New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 9, 2014
19:43 EDTPFE, BAYRY, JNJFDA panel recommendation may give boost to Bayer's Aleve, WSJ says
An FDA advisory committee of medical experts will be working this week to determine whether the drug naproxen, sold as Aleve by Bayer (BAYRY ), poses little to no heart danger, says the Wall Street Journal. The advisory committee is evaluating a current labeling requirement that non-steroidal anti-inflammatory drugs, known as NSAIDs, carry a "heart warning", says WSJ, adding that a possible outcome of the review may be"a cleaner label and major marketing advantages for Aleve". Note that Pfizer (PFE) manufactures competing NSAIDs Celebrex and Advil, while Johnson & Johnson, (JNJ) is the maker of of Motrin, also an NSAID. Reference Link
News For BAYRY;PFE;JNJ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 >>
November 19, 2015
06:46 EDTPFECiti not seeing how Treasury can stop Pfizer, Allergan deal
Citi analyst Liav Abraham says he struggles to see what the Treasury can do to stop Pfizer's (PFE) potential acquisition of Allergan (AGN). The Treasury's plans announced yesterday to implement further actions to curb tax inversions were likely spurred by the "imminent announcement" of a Pfizer, Allergan merger, Abraham tells investors in a research note. The developments were likely factored into Pfizer and Allergan's assumptions when entering into merger discussions, the analyst adds. He expects a deal to be announced over the near term and keeps a Buy rating on Allergan with a $360 price target. Bloomberg reported last night that Pfizer is nearing an acquisition of Allergan at $370-$380 per share. The Botox maker closed yesterday at $310.38.
06:06 EDTPFEAllergan weekly volatility elevated into reports of near deal with Pfizer
Subscribe for More Information
05:29 EDTPFEServier exercises licensing option with Cellectis for UCART19
Subscribe for More Information
November 18, 2015
20:00 EDTPFEPfizer nears deal for Allergan at $370-$380 per share, Bloomberg says
Subscribe for More Information
19:00 EDTPFEPfizer nearing acquisition of Allergan at $370-$380 per share, Bloomberg says
Subscribe for More Information
17:00 EDTPFETreasury Department to release new 'guidance' deterring tax inversions, WSJ says
Subscribe for More Information
08:11 EDTPFE, JNJIMS Health forecasts global drug spending to increase 30% by 2020 to $1.4T
Subscribe for More Information
08:11 EDTJNJAduro Biotech receives milestone payment from Janssen
Aduro Biotech (ADRO) announced that it has received a milestone payment from Janssen Biotech (JNJ) for Aduro's submission of an Investigational New Drug, or IND, Application to the FDA for ADU-741, a LADD immunotherapy product candidate for the treatment of prostate cancer. The IND will enable Janssen, Aduro's license partner for ADU-741, to initiate a multi-center Phase 1 trial to evaluate the safety and immunogenicity of intravenous administration of ADU-741 in patients with metastatic castration-resistant prostate cancer.
08:06 EDTPFEPfizer says Phase 3 XALKORI trial shows 'positive' results
Subscribe for More Information
07:02 EDTPFEMerck KGaA, Pfizer win FDA breakthrough therapy designation for Avelumab
Subscribe for More Information
06:09 EDTPFEValeant's Addyi sees hardly any sales, Bloomberg says
Subscribe for More Information
06:03 EDTBAYRYBayer says not looking to sell crop chemicals business, Reuters reports
Bayer (BAYRY) says its Bayer CropScience unit is an "integral part" of the company and that the division is not for sale, Reuters reports. Bayer's comments come after Monsanto (MON) executives said that it is in internal discussions about tie-ups in the industry. Reference Link
November 17, 2015
05:22 EDTPFEStocks with implied volatility movement; P PFE
Stocks with implied volatility movement; Pandora (P) 104, Pfizer (PFE) 29 according to iVolatility.
November 16, 2015
14:38 EDTJNJGenmab confirms FDA approval of Darzalex
Subscribe for More Information
13:32 EDTPFECantor helps Moelis clinches advisory role for Pfizer, Reuters reports
Subscribe for More Information
13:09 EDTJNJFDA approves Darzalex to treat multiple myeloma
Subscribe for More Information
09:59 EDTPFEOmega bought Valeant in Q3, sold some SuneEdison
Leon Cooperman's Omega Advisors gave a quarterly update on its stakes in a filing this morning, disclosing its positions as of September 30. NEW STAKES: Pfizer (PFE), Valeant (VRX) Walgreens Boots Alliance (WBA), TerraForm Global (GLBL), Cigna (CI). INCREASED STAKES: Google Class A (GOOGL), Facebook (FB), Delta Air Lines (DAL). DECREASED STAKES: SunEdison (SUNE), Shire (SHPG), Citi (C), KAR Auction (KAR), LyondellBasell (LYB). LIQUIDATED STAKES: McKesson (MCK), 21st Century Fox (FOXA), General Motors (GM), QEP Resources (QEP), eBay (EBAY).
06:33 EDTPFEPfizer, Allergan deal brings focus on U.S. tax-inversion deals, Reuters says
Pfizer's (PFE) takeover bid for Allergan (AGN) has refocused financial markets over a potential move by the U.S. Treasury Department against tax-inversion deals, Reuters reported Friday. The outlook for such a move remained unclear on Friday, the report says. Reference Link
November 15, 2015
18:13 EDTPFEAllergan, Pfizer targeting late November merger deal, FT says
Subscribe for More Information
13:04 EDTBAYRYBayer shares could advance 25% in a year, Barron's says
Subscribe for More Information
1 | 2 | 3 | 4 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use